[Interferon-alpha-induced XXXX . A retrospective analysis of the literature and personal experiences].

@entity1 @entity1375 @entity1378 @entity792 @entity3027 @entity1374
This paper tries to evaluate the importance of @entity3027 induced @entity1374 . Based on our own experience and reported data we present the results obtained in a total of 588 @entity1 , in whom thyroid function and thyroid antibody occurrence was monitored during therapy with @entity3027 : About 10% of these @entity1 developed @entity1374 during @entity3027 treatment. Half of them reacted with @entity1375 , 3% with @entity1378 and in 2% a biphasic ( @entity1378 followed by @entity1375 ) pattern of reaction was observed. The frequency of these @entity1374 was increased in female @entity1 and in @entity1 with preexisting thyroid antibodies. The risk to develop @entity1374 is reduced to 7% in @entity1 with no pretherapeutic thyroid antibodies. The evolution of the thyroid ailment is variable and therefore unpredictable. In many @entity1 there is no need to stop treatment with @entity3027 nor to treat the @entity1374 specifically. @entity3027 induced @entity792 seem to be etiologically important for the development of @entity1374 during @entity3027 . The reported data allow in our view some basic recommendations for the clinician: thyroid function and thyroid antibodies should be evaluated before the start of treatment with @entity3027 . During therapy with @entity3027 these parameters should be regularly (eg every 4 months) monitored. In @entity1 with @entity1374 already before @entity3027 the control intervals should not be longer than every two months.
